Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
Pfizer(PFE) stock is priced at $27.50, giving the company a market capitalization of 156.4B. It carries a P/E multiple of 20.15 and pays a dividend yield of 6.3%.
As of 2026-03-19, Pfizer(PFE) stock has fluctuated between $27.09 and $27.53. The current price stands at $27.50, placing the stock +1.5% above today's low and -0.1% off the high.
Pfizer(PFE) shares are trading with a volume of 3.03M, against a daily average of 42.72M.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.
PFE News
Pfizer (PFE) announced positive topline results from the Phase 3 TALAPRO-3 study of talzenna – talazoparib -, an oral poly ADP-ribose polymerase, or PARP, inhib...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is running a Phase 1 study called “A PHASE 1, OPEN-LABEL, SINGLE-DOSE,...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. The phase 1 study “AN OPEN-LABEL PHASE 1 STUDY TO INVESTIGATE PF-08046031 IN ADULTS WITH...
Analyst ratings
55%
of 29 ratingsMore PFE News
Key Points Pfizer and Novo Nordisk look cheap in more ways than one. Pipeline progress could help improve their financial results. Exelixis is a small but su...
Pfizer (NYSE:PFE) reported positive randomized Phase 2 results for atirmociclib, its next generation CDK4 inhibitor, in advanced or metastatic breast cancer. T...
Pfizer Inc. (NYSE:PFE) on Tuesday announced topline results from the Phase 2 FOURLIGHT-1 study in pretreated metastatic breast cancer patients. The trial, whic...
Anytime is a great time to invest in stocks. The catch is that you must choose the right stocks. The current market dynamics, including high volatility and wor...
Pfizer (PFE) announced on Tuesday that its investigational breast cancer therapy, atirmociclib, as part of a combination regimen, reached the main goal in a lat...
Pfizer (PFE) announced topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant...
HSBC raised the firm’s price target on Pfizer (PFE) to $32 from $29 and keeps a Buy rating on the shares. The firm says the uncertain macro backdrop, rising geo...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.